1 that focused on a recently published study by Fuchs and colleagues. 2 We agree with the author that the anti-VEGF monoclonal antibody ramucirumab represents a new bio logical therapy for gastric cancer; however, we disagree with the statement that ramuciru mab has been shown to be efficacious in most subgroups of patients. The lack of efficacy of several new drugs in six recent large phase III clinical trials that include this agent and one prospective random ized trial in women with this disease is concerning. [2] [3] [4] [5] [6] [7] [8] Our concerns are based on two facts. First, in Figure 3 in the article by Fuchs and colleagues, 2 the hazard ratio (HR) in women is 1.431 (0.852-2.405, 95% CI), whereas for men the HR is 0.676 (0.499-0.916, 95% CI). Because the total number of research participants of men and women in this study are both more than 100 (248 and 107, respectively), the results for both men and women seem statistically trustworthy. Therefore, from these data, we can conclude that the drug is not effective in women. Second, we searched PubMed for the results of clinic trials published from January 2011 to February 2014, using the key words 'gastric cancer trial phase' or 'gastro-oesophageal junction trial phase' or 'gastro esophageal adenocarcinoma trial phase' . We identified six studies-in addition to the article by Fuchs et al. 2 -that included ≥100 patients and that had analysed the HR separately for men and for women. [3] [4] [5] [6] [7] [8] Notably, the HR for women in five of these six trials was higher than the HR for men ( Table 1 ). The only exception is the median overall survival (months) in the trial noted for those patients treated with capecitabine and cisplatin with or without cetuximab who had previously untreated advanced-stage gastric cancer; 6 
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Lishi Wang, Yan Jiao, Yun Jiao, Yanhong Cao and Weikuan Gu the HR for men and women was similar, 1.04 versus 1.00, respectively. However, the study reported a negative result, indicating that addition of cetuximab to capecitabine and cisplatin provided no additional benefit to chemotherapy alone. Furthermore, the median overall survival durations for women in both treatment arms (7.2 and 8.7 months, for those receiving capecitabine and cisplatin with or without cetuximab, respectively) in this trial are lower than the respective results seen in men (10.9 and 11.0 months, respectively).
The lack of efficacy observed in women with gastric cancer compared with men in these trials is most likely due to incidence and mechanistic differences that are related to gender differences. Although the molecu lar mechanisms for gender differences in gastric cancer are not well understood, there are data that strongly support the existence of such differences. First, it is known that there is a gender difference in the incidence of this disease. 9 Incidence of gastric cancer in women is much less than that in men. 10 Second, differences have been Abbreviations: DFS, disease-free survival; HR, hazard ratio; M, men; PFS, progression-free survival; RFS, recurrence-free survival; W, women.
reported in the survival rates between men and women with metastatic gastric cancer.
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These data indicate that in women and men, biological and genetic components contribute differently to the susceptibility and to the progression of the disease. For example, in the trials of doxifluridine, 3 perioperative enteral immunonutrition, 4 postoperative antimicrobial prophylaxis, 5 and the combi nation of capecitabine and oxaliplatin (Table 1) , 8 the outcome of treatment of gastric cancer with these drugs showed gender differences. Furthermore, for some drugs, there are gender differences in terms of how the pathways targeted by these agents are regulated. For example, the mono clonal antibody ramucirumab directed against VEGFR-2, and the anti-EGFR antibodies panitumumab and cetuximab show hormonal differences and gender-related differential expression. 12, 13 Therefore, to a certain degree, the outcome of gender differences from treatments with these drugs is expected.
Another concern is that the protocols in the trials are the same for men and women, and do not consider these gender differences. The effect of a drug treatment is based on a complicated network of interactions between the drug, tumour tissues and the whole human body. Theoretically, for the drugs showing gender specificity, research on the gender differences should be done before starting the clinical trial, to optimize the conditions for both men and women. All the factors that can influence the effect of drugs, such as body mass, hormo nal levels, and age, should be considered. We feel that neglecting the subgroup of women in the biomedical community of patients with gastric cancer is a serious problem. Undoubtedly, the incidence of the disease is greater in men; should the drugs then be designed and developed exclusively for the benefit of the male population? If that is the case, should women be excluded from such trials? What is the benefit for a woman to be enrolled in a trial for a drug that has not been developed to target 'her particular disease'? The inclusion of patients in general in clinical trials, and women in this specific situation, should be based on scientific knowledge.
